

# Global Clinical Development Pipeline

## Phase 1

### Sonrotoclast BCL2i

- 101/102 B-cell malignancies
- 103 AML/MDS
- 105 MM t(11;14)

### BGB-16673 BTK CDAC

- 102 B-cell malignancies
- 104 B-cell malignancies<sup>†</sup>

### BGB-21447 next gen BCL2i

- 101 B-cell malignancies

### Tislelizumab PD1 mAb

- 103 SubQ formulation

### Ociperlimab TIGIT mAb

- 900-105 NSCLC dose confirmation
- 101 R/R DLBCL

### BGB-15025 HPK1i

- 101 Solid tumors

### BGB-26808 HPK1i

- 101 Solid tumors

### BGB-30813 DGKζi

- 101 Solid tumors

### BGB-A3055 CCR8 mAb

- 101 Solid tumors

### BGB-24714 SMAC mimetic

- 101 Solid tumors

### BGB-43395 CDK4i

- 101/102 BC & Solid tumors

### BG-68501<sup>1</sup> CDK2i

- 101 BC & Solid tumors

### BG-C9074<sup>2</sup> B7H4 ADC

- 101 BC & Solid tumors

### Xaluritamig<sup>3</sup> STEAP1 x CD3 BsAb

- 201 80146 mCRPC

### BGB-45035 IRAK4 CDAC

- 101 Immunology & Inflammation

### BGB-C354 B7H3 ADC

- 101 Solid tumors

### BGB-R046 IL-15 prodrug

- 101 Solid tumors

### BGB-B2033 GPC3 x 4-1BB BsAb

- 101 Solid tumors

### BGB-B3227 MUC1 x CD16A BsAb

- 101 Solid tumors

### BG-C477 CEA ADC

- 101 Solid tumors

### BG-T187 EGFR x MET TsAb

- 101 Solid tumors

### BG-C137 FGFR2b ADC

- 101 Solid tumors<sup>†</sup>

### BGB-53038 PanKRASi

- 101 Solid tumors<sup>†</sup>

### BG-58067 MTA Coop. PRMT5i

- 101 Solid tumors<sup>†</sup>

## Phase 2

### Zanubrutinib BTKi

- 215 B-cell malignancies
- 218 CD79B R/R DLBCL
- 217 Lupus nephritis

### BGB-16673 BTK CDAC

- 101 R/R MCL, R/R CLL

### Sonrotoclast BCL2i

- 201 R/R MCL
- 202 R/R CLL
- 203 R/R WM
- 204 TN CLL/SLL<sup>†</sup>

### Blinatumomab<sup>3</sup> CD3 x CD19 BsAb

- 201 90359 Pediatric R/R BP-ALL

### LBL-007<sup>4</sup> LAG3 mAb

- 201 MSS-CRC
- 202 1L ESCC

### BGB-A445 OX40 mAb

- 201 Melanoma, UC

### Umbrella Studies IO Combos

- LC-201 1L NSCLC
- LC-203 2L+ NSCLC
- LC-202 Neoadj NSCLC
- HNSCC-201 1L HNSCC

### Tarlatamab<sup>3</sup> DLL3 x CD3 BsAb

- 202 30273 3L SCLC

## Phase 3

### Zanubrutinib BTKi

- 306 TN MCL
- 308 R/R MZL, R/R FL
- 309 pMN

### Sonrotoclast BCL2i

- 301 TN CLL

### Tislelizumab PD1 mAb

- 310 1L UBC
- 311 LA ESCC
- 314 R/R cHL

### Pamiparib PARPi

- 302 2L MTx gBRCAm PSOC

### Ociperlimab TIGIT mAb

- 302 1L NSCLC PDL1-high

### Zanidatamab<sup>5</sup> HER2 BsAb

- 301 1L HER2+ GEA

### Tarlatamab<sup>3</sup> DLL3 x CD3 BsAb

- 202 10004 2L SCLC
- 202 00041 1L ES-SCLC
- 202 30016 LS-SCLC

## Registration

### Zanubrutinib BTKi

- 114 Tablet formulation (US, EU, Others)
- 304 TN CLL/SLL (JP)
- 305 R/R CLL/SLL (JP)
- 302 TN WM (JP)

### Tislelizumab PD1 mAb

- 305 1L GC/GEJC ITT (US, EU)
- 306 1L ESCC (US, EU, JP)
- 302 2L ESCC (JP)
- 302 2L ESCC alt dosing (US)

### Zanidatamab<sup>5</sup> HER2 BsAb

- 203 HER2+ 2L BTC (CN)

- Heme
- Lung
- GI
- Breast/Gyn
- Pan-Tumor/Other
- Non-Oncology

Registration includes select accepted submissions in major markets.

<sup>†</sup> Trial is listed on clinicaltrials.gov but may not have subjects enrolled.

<sup>1</sup>Ensem collaboration, <sup>2</sup> DualityBio collaboration, <sup>3</sup> Amgen collaboration, <sup>4</sup> Leads Biolabs collaboration, <sup>5</sup> Zymeworks/Jazz collaboration.

Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details.